ABSTRACT
INTRODUCTION
N-3 polyunsaturated fatty acids (PUFA) have been well studied during the last decades since they regulate in vivo many physiological functions. It is assumed that long-chain n-3 PUFA have beneficial effects on cardiovascular and coronary artery diseases (1, 2) , rheumatoid arthritis (3) (4) (5) , blood pressure control and heart hypertension (6, 7), and they might prevent multiple sclerosis and Alzheimer's diseases (8) (9) (10) (11) . More recently, new lipid mediators deriving from eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids have been described. Among them, resolvins are oxygenated molecules that derive from EPA and DHA (12, 13) and are separated into two series: E-series (from EPA) and D-series (from DHA) (14) . In addition to the D-series resolvins, protectin D1 (PD1) is produced from DHA via a mechanism involving an epoxide intermediate (15) , as well as maresin which can be produced by macrophages (16) . PD1 has been described as potent anti-inflammatory agents without anti-aggregatory effect (15, 17) . In contrast, protectin DX (PDX), an isomer of PD1, which derives from DHA via a double lipoxygenation, reveals inhibitory effects on blood platelet aggregation. PDX inhibits platelet cyclooxygenase (COX)-1 and antagonizes the thromboxane A 2 -induced aggregation (18) . We found that di-hydroxylated compounds called poxytrins, synthesized from C20 and C22 PUFA via the soybean and having the same E,Z,E conjugated triene motif, including PDX, are all anti-aggregatory agents (19) . On the other hand, very few data are available concerning the oxygenated metabolism of alpha-linolenic acid (18:3n-3 or ALA). Investigations relating to ALA are particularly relevant since this fatty acid is taken in large amount (1-2 g/day in human adults) as a nutrient and hardly accumulates in plasma, suggesting an active metabolism. Moreover, its conversion into EPA and DHA is relatively limited. A conversion of ALA into its longchain product DHA was found around 1% in men (20) and 2% in young women (21) .
Formation of 9,16-dihydroxyoctadecatrienoic acid (9,16-di-HOTE) isomers from ALA by sLOX-2 have already been reported first in 1984 by Vliegenthart et al. (22) without establishing the double bond configuration nor the stereochemistry of the asymmetric carbons. Further studies presented by Sok and Kim (23, 24) reported four isomers but again their characterisation was not fully established and especially that of the all trans isomers. In 1991 Grechkin et al. (25) showed that potato tuber lipoxygenase (LOX) generated mainly 9(S)-hydroperoxy-octadeca-10E,12Z,15Z-trienoic acid (9(S)-HpOTE) which is different from the sLOX which produces mainly 13(S)-hydroperoxy-9Z,11E,15Z-octadecatrienoic acid (13(S)-HpOTE). Also, two compounds after reduction by NaBH 4 were characterized as 9,16-di-HOTE (10E,12Z,14E) except for the stereochemistry of the carbon 16 which remains undetermined and trans isomers were not detected. Moreover, the biological properties of the 9,16-di-HOTE isomers have not been investigated yet. Since ALA is the most abundant n-3 PUFA in human diet, it is relevant to investigate more thoroughly its oxygenated metabolism, especially by 15-LOX that is expressed in blood leukocytes and most endothelial cells, and compare the biological activity of the metabolites to that of PDX, the main 15-LOX product of DHA. were from Interchim. Organic solvents were from Carlo-Erba. All chemicals used were reagent grade or with the highest quality available.
MATERIALS AND METHODS

Biosynthesis of 9,16-dihydroxy-ALA derivatives
ALA was incubated with sLOX (Type 1-B) in sodium-borate buffer. Synthesized hydroperoxides were reduced by sodium borohydride (NaBH 4 ) as previously described (18) .
After acidification, mono-and di-hydroxylated fatty acids were extracted on a C18 solidphase cartridge as previously described (18) . Commercial 9(S)-HOTE, 9(S)-HpOTE and the home-made racemic 9(±)-HOTE chemically produced by oxygen treatment of ALA and isolated by reverse phase high-performance liquid chromatography (RP-HPLC), were further treated by sLOX in order to generate 9,16-di-HOTEs with defined stereochemistry.
Purification of mono-and di-hydroxylated fatty acids
Mono-and di-hydroxylated fatty acids were analyzed by RP-HPLC on a Waters XBridge C18 column (4.6 × 250 mm, 3.5 µm) by using a linear solvent gradient: solvent A was a mixture of acetonitrile/water acidified to pH 3 (10/90, v/v), and solvent B was acetonitrile. The flow was set at 1 mL/min. Mono-and di-hydroxylated fatty acids were detected with a diode array detector at 235 nm and 270 nm, respectively, and collected separately.
GC-MS analysis of mono-and di-hydroxylated fatty acids
Mono-and di-hydroxylated fatty acids isolated by RP-HPLC were hydrogenated using PtO 2 as a catalyst, and then derivatized into methyl esters and TMS ethers. Samples were then analyzed by GC-MS using the electron impact ionization (EI) mode in order to localize the hydroxyl groups on the fatty chain (18) .
Nuclear magnetic resonance (NMR) of 9, 16-di-HOTEs
The NMR experiments were performed on a Bruker-Biospin NMR spectrometer operating at reduced by NaBH 4 . Lipids were extracted after acidification to pH 3 with acetic acid and dihydroxylated metabolites were purified as described above.
Preparation of cell suspensions
Platelet suspensions: Venous blood from healthy volunteers who had not taken any medication for at least one week was collected at the local blood bank ("Etablissement Français du Sang") (EFS). Blood was drawn onto anticoagulant and centrifuged at 200 g for 15 min at 20°C to obtain the platelet-rich plasma (PRP) upper phase, and platelets were isolated as described previously (34). Briefly, PRP was acidified to pH 6.4 with 0.15 M citric acid and immediately centrifuged at 900 g for 10 min, and platelet pellets were suspended into Tyrode-HEPES buffer (140 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl 2 , 12 mM NaHCO 3 , 0.41 mM NaH 2 PO 4 , 5 mM HEPES, and 5.5 mM glucose, pH 7.35).
Leukocyte suspensions: Leukocytes were isolated from blood obtained from EFS, as previously described (35). Dextran (2% final concentration) was added to the lower phase obtained after the first blood centrifugation at 200 g. Erythrocytes were then sedimented under gravity for 45 min at 15°C. The erythrocyte-depleted supernatant containing leukocytes was centrifuged at 400 g for 10 min. The resulting leukocyte-rich pellets were re-suspended into saline buffer, and layered over a Ficoll-Paque Plus (density 1.077). After centrifugation, the fraction above the erythrocyte layer was removed and centrifuged, and re-suspended in water for 20 s to lyse the contaminant erythrocytes. Osmotic pressure was immediately restored with NaCl, followed by centrifugation, which provided a white pellet consisting of whole leukocytes that was re-suspended into Tyrode-HEPES buffer. The morphological examination and trypan blue exclusion tests were performed to determine the cell count and purity, and evaluate the viability of neutrophils.
Measurement of platelet aggregation and incubation with human leukocytes
Blood platelet aggregation was determined by the turbidimetric method of Born (36) using a dual aggregometer (ChronoLog, Havertown, PA, USA). To measure changes in the light transmission rate, 400 µL of platelet suspension was heated at 37°C for 1 min with stirring, incubated in the presence or absence of di-hydroxylated compounds (added in 1 µL of ethanol) for 1 more min, and then with collagen as a platelet aggregatory agent for 4 min at 37°C. Concentrations of collagen were adjusted to obtain nearly 75% aggregations for control platelets.
Isolated human leukocytes, suspended in a Tyrode-HEPES buffer containing 2 mM Ca 2+ were pre-incubated in the presence or absence of 1 µM of different 9,16-di-HOTE isomers for 3 min at 37°C, and triggered with 1 µM ionophore A23187 plus 10 µM arachidonic acid for 10 min. The reaction was stopped by acidifying the media to pH 3 with acetic acid. The oxygenated metabolites were then extracted as previously described (18). 
GC-MS measurement of purified cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) products
Statistical analysis
All results are expressed as means ± standard error of the mean (SEM) or means ± standard deviation (SD). P < 0.05 was set as the level of significance as determined by 2-tailed Student's t tests. One-way ANOVA analysis was used to assess differences between groups.
RESULTS
Characterization of metabolites obtained from ALA incubated with sLOX
From ALA incubated with sLOX as described in Materials and Methods, hydroxylated derivatives analyzed by RP-HPLC provided one main compound detected at 50 min with a  max of 235 nm (Fig. 1A ). Its retention time and its UV spectrum were similar to that of commercial 13(S)-HOTE (result not shown).
Regarding di-hydroxylated products (Fig. 1B) , and in contrast to DHA which is only converted into one major di-hydroxylated metabolite called PDX, four di-hydroxylated isomers were detected from ALA. They all exhibited characteristic UV spectra with a maximum absorption ( max ) at 270 nm with two shoulder peaks at 260 nm and 280 nm, indicating the presence of a conjugated triene. Moreover, the UV spectra of the two first isomers eluted at 32.1 and 32.6 min are superimposable to that of commercial 12-epi-all transleukotriene B 4 (12-epi-all trans LTB 4 ) with an E,E,E conjugated triene geometry (result not shown), whereas the UV spectra of the two other isomers eluted at 33.2 and 33.5 min are superimposable to that of PDX, suggesting an E,Z,E geometry of these conjugated trienes (Fig. 1B) . The spectra of these four isomers differ from those with a Z,E,E configuration such as LTB 4 and 12-epi-LTB 4 (result not shown).
Localization by GC-MS of hydroxyl groups on the fatty chain
Mono-and di-hydroxylated compounds from ALA mentioned above were hydrogenated and derivatized as methyl esters and TMS ethers as described in "Materials and Methods" and analyzed by GC-MS using the EI mode.
The EI mass spectrum of the hydrogenated mono-hydroxylated ALA derivative ( Fig. 2A) shows characteristic ions at m/ Determination of carbon stereochemistry of di-hydroxylated metabolites synthesized from ALA Commercial 9(S)-HOTE and racemic 9(±)-HOTE, prepared as described in "Materials and Methods", were incubated separately with sLOX as described with ALA, and further reduction by NaBH 4 . 9(S)-HOTE was metabolized into a main compound eluted at 33.4 min (Fig. 3A) . This peak was attributed to 9(S),16(S)-di-HOTE because sLOX produces almost exclusively the S enantiomer via a double dioxygenation mechanism (40), although soybean LOX generates almost exclusively 13(S)-HpOTE from ALA (40) as it was already shown (Fig. 1A) . On the other hand, 9(R),16(S)-di-HOTE peak, eluting at 33.7 min, was also formed ( This assignment was also confirmed by the fact that chromatograms of di-hydroxylated isomers from 9(S)-HpOTE and 9(S)-HOTE were almost identical, but different from that with ALA as a substrate (Fig. 4) . As a matter of fact, another major E,Z,E product (RT 33.5 min, see also Fig 1B) is likely 9(R),16(S)-di-HOTE. In addition, the same compound appeared when the racemic 9(±)-HOTE was incubated with sLOX ( Fig. 3B , RT 33.7 min).
However, we may assume that the two all trans diastereoisomers, synthesized from ALA, as this will be confirmed by NMR below, (RT 32.1 and 32.6 min) ( Fig.1B) ), as it can be seen in Fig. 5 and Fig. 6 . The resonance assignment has been determined by using DQF COSY, while a large part of the J-couplings were measured through the analysis of 2D J-resolved spectra (data not shown). In such a way, it was possible to determine that the 1 
Metabolism of ALA by human recombinant 15-LOX-2
This experiment was done to check whether the human recombinant 15-LOX type 2 is also able to synthesize such metabolites. For this purpose, ALA, 9(S)-HOTE and 9(±)-HOTE were separately incubated with this enzyme. We found that human recombinant 15-LOX-2 is able to convert ALA into 13-HOTE as previously described with the soybean 15-LOX (result not shown). However, ALA was less markedly metabolized into di-hydroxylated fatty acids, the main ones being all trans 9,16-di-HOTE isomers. Interestingly enough, the monohydroxylated derivatives 9(S)-HOTE and 9(R)-HOTE were well converted into 9(S),16(S)-
E,Z,E-di-HOTE and 9(R),16(S)-E,Z,E-di-HOTE, respectively (result not shown) by the human recombinant LOX.
Inhibitory effect of 9,16-di-HOTEs on COX-1 and anti-aggregatory effects
The inhibition of sheep cyclooxygenase-1(COX-1) by different 9,16-di-HOTE isomers was tested at 1 µM by measuring both PGD 2 and E 2 as described in "Materials and Methods".
Results reported in Table 1 show that 1 µM of 9(S),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic and 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acids decreased significantly the synthesis of both PGD 2 and E 2 by around 28% and 38%, respectively. Such results are in agreement with previous data showing that poxytrins, characterized by a E,Z,E triene geometry, are inhibitors of platelet COX-1 (19) whereas the all trans isomers are inactive.
Such results are in agreement with data relating to platelet aggregation induced by collagen.
Platelet aggregation was significantly decreased by 64% and 65% in presence of 1 µM
9(S),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acid and 9(R),16(S)-dihydroxy-
10E,12Z,14E-octadecatrienoic acid, respectively (Fig. 7) . In addition, the aggregation started to be reversed from two minutes following the agonist addition. As previously shown (19) , all trans isomers had no effect on platelet aggregation.
Anti-inflammatory effect of 9,16-di-HOTEs
After showing that 9,16-dihydroxy-10E,12Z,14E-octadecatrienoic acid isomers possess antiaggregatory properties as those previously described for poxytrins (19) , it was important to know whether such di-hydroxylated compounds issued from ALA may exhibit antiinflammatory properties. We then investigated the effects of 9,16-di-HOTEs on cyclooxygenase-2 (COX-2) as well as the 5-lipoxygenase pathway.
 Effect of 9,16-di-HOTEs on human recombinant COX-2
The inhibition of human recombinant COX-2 by 1 µM of 9,16-di-HOTE isomers were assessed by measuring PGD 2 and E 2 as described above. Results reported in Table 1 show that
9(S),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic and 9(R),16(S)-dihydroxy-10E,12Z,14E-
octadecatrienoic acids significantly inhibited COX-2 activity by 9% and 21% respectively.
 Effect of 9,16-di-HOTEs on the metabolism of arachidonic acid by the human PMN 5-lipoxygenase
The inhibition of human 5-lipoxygenase pathway by 1 µM of 9,16-di-HOTE isomers was assessed by measuring the following metabolites: 5(S)-HETE, LTB 4 and its two all trans isomers. As reported in Table 2 , only 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acid isomer significantly decreased the formation of leukotrienes and 5(S)-HETE by around 10% and 20%, respectively. All other isomers did not inhibit such a production (results not shown). Such data suggest that the inhibition concerns only 5-lipoxygenase but not LTA 4 hydroxylase. Taken together, these data suggest that 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acid isomer may have a potential anti-inflammatory effect.
DISCUSSION
ALA is an essential fatty acid present in vegetable oils, and as such available in human diet. It is the precursor of EPA and DHA, but its conversion into EPA and DHA is rather limiting with around 10% to the former and further 10% to the latter, which means only 1% conversion of ALA to DHA (47, 48) . ALA is also rather well -oxidized (49, 50) , that could partially explain its low accumulation in plasma and tissues. In addition, we describe here a pathway which could explain some beneficial effects of ALA in the vascular system at large by reducing both the production of pro-inflammatory eicosanoids PGD 2 /E 2 and LTB 4 (51-53).
We recently showed that a new di-hydroxylated metabolite from DHA called PDX, which is an isomer of the anti-inflammatory protectin D1, exhibits anti-aggregatory properties, both by inhibiting collagen-induced prostanoids production, including thromboxane A 2 , and thromboxane A 2 -induced aggregation (19) . In the present paper we report the full characterization of the lipoxygenation of ALA, and the anti-inflammatory and antiaggregatory effects of two LOX end-products. The structure of the four LOX metabolites that we herein describe have already been partially reported (23, 24), but the proposed stereochemistry structures of the 9(S),16(R)-di-HOTE do not fit with our experimental data.
On the other hand, their biological properties have not been investigated.
Our data show that ALA is mainly converted into its 13-oxygenated derivative 13-HOTE by 15/6-lipoxygenase. However, formation of a small amount of the 9-oxygenated product 9-HOTE could also be observed. In contrast to DHA, which is converted into only one main dihydroxylated compound (PDX) via a double lipoxygenation, four di-hydroxylated compounds were observed from ALA following incubation with 15-lipoxygenase, characterized as 9,16-di-HOTEs. The stereochemistry of these di-hydroxylated compounds was assessed by incubating 9(S)-HOTE and racemic 9(±)-HOTE separately with sLOX (see the above results).
The UV spectra of the two main di-hydroxylated products are superimposed to that of PDX, which possesses a E,Z,E conjugated triene geometry. The diastereoisomers are likely produced via a dioxygenation mechanism as previously described for PDX (18) and these two compounds are likely to have an E,Z,E conjugated triene geometry. Such a geometry was further confirmed by high field NMR which allowed to determine precisely the 1 H-1 H Jcouplings among the protons bound to the sp 2 carbons in C=C double bonds. The geometry of the conjugated trienes of two additional but less abundant (around half the amount of the
E,Z,E-9(S),16(S)-di-HOTE and 9(R),16(S)-di-HOTE) di-hydroxylated products was supposed
to be E,E,E since their UV spectra were superimposed to that of all trans LTB 4 , which has such an E,E,E conjugated triene geometry. This all trans geometry was also confirmed by NMR to determine the previously shown for PDX (18) , whereas the all trans 9,16-di-HOTE isomers might derive from unknown intermediates.
We also investigated the metabolism of ALA incubated with human recombinant 15-LOX-2.
Interestingly, 9(S)-HOTE or 9(R)-HOTE were both well converted into the corresponding 9,16-di-HOTEs whereas ALA was less efficiently metabolized into those di-hydroxylated fatty acids than by sLOX. Such a result might be biologically relevant since 9(S)-HOTE can be produced through cyclooxygenases, and 9(R)-HOTE can be produced via aspirinated COX-2, both in an aborted cyclooxygenation process (54) .
The present study also shows some biological effects of the E,Z,E di-hydroxylated 9,16-di-HOTE isomers. We observed that 9(S),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic and 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acids decreased significantly prostaglandin synthesized by recombinant COX-1. Moreover, these E,Z,E isomers inhibit platelet aggregation triggered by collagen both by decreasing the extent of aggregation and making it partially reversible (Fig. 7) . However, these E,Z,E di-hydroxylated ALA metabolites appear to be less potent inhibitors than PDX under the same conditions, although the anti-aggregatory effects observed is in agreement with our previous data showing that poxytrins, characterized by an E,Z,E conjugated triene, are inhibitors of COX-1 (19).
COX-2 is an inducible enzyme becoming abundant at sites of inflammation, and is upregulated in various carcinomas, having a central role in tumorigenesis (55) . The inhibition of COX-2 is a major mode of action to reduce inflammation (56) . In our study, we found that It is interesting to note that in all the tests evaluated, the E,Z,E 9(R),16(S) isomer was a more potent inhibitor than the E,Z,E 9(S),16(S) one. This reinforces the interest of the 15-lipoxygenation of 9(R)-HOTE produced by aspirinated COX-2 (54) to synergize with aspirin in atherothrombogenesis.
In conclusion, we observe from the present study that four di-hydroxylated compounds are produced from ALA treated by sLOX. They are 9(R),16(S)-dihydroxy-10E,12E,14E-octadecatrienoic, 9(S),16(S)-dihydroxy-10E,12E,14E-octadecatrienoic, 9(S),16(S)-dihydroxy-10E,12Z,14E-octadeca trienoic, and 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acids. Interestingly, 9,16-dihydroxy-10E,12Z,14E-octadecatrienoic acid isomers exhibit antiaggregatory properties as other poxytrins (19) . In addition, 9(R),16(S)-dihydroxy-10E,12Z,14E-octadecatrienoic acid, which can be produced from 9(R)-HOTE by aspirinated COX-2, inhibits both cyclooxygenases and the 5-lipoxygenase pathway and appears to be a potential anti-inflammatory compound in vitro.
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